This editorial refers to 'Lamin A/C cardiomyopathy: young onset, high penetrance, and frequent need for heart transplantations' † , by N.E. Hasselberg et al., on page 853.
Lamin A and C are nuclear matrix proteins which are located on the nuclear surface of the inner nuclear membrane. Both proteins are encoded by the same gene (LMNA) mapped to the region 1q21.2-1q21.3 with 12 exons. Alternative splicing within exon 10 generates two different mRNAs that code for lamin A and C. Skeletal and myocardial laminopathies caused by mutations in this gene were first reported in 1999 (for reviews, see Fatkin et al., 1 Bonn et al., 2 Shackleton et al., 3 and
Genschel and Schmidt 4
). The clinical spectrum ranges from LMNArelated congenital muscle dystrophy to later onset Emery-Dreifuss dystrophy, limb girdle dystrophy, familial partial lipodystrophy, Hutchinson-Gilford progeria syndrome to dilated cardiomyopathy, with conduction system disease depending on the form and site of the mutation. Patients with a predominant cardiac phenotype are characterized by atrial arrhythmia, progressive atrioventricular conduction disease, and ventricular tachycardia, that often precede the development of systolic dysfunction. To date, several other rare inherited human diseases with overlapping phenotypes have been linked to LMNA mutations, suggesting a clinical continuum between these clinical entities. 5, 6 The cause of laminopathies-not only those with predominant cardiac involvement-are mutations along the entire LMNA gene, although the majority are missense mutations in the central rod domain. 1 The pathophysiological mechanisms are poorly understood as LMNA mutations may have effects on nuclear fragility, alterations in cellular signalling, and gene expression, resulting in abnormal interaction between lamins and other nuclear proteins such as desmin, and abnormal processing of pre-lamin A.
7,8
Lamin A/C mutations in dilated cardiomyopathy Dilated cardiomyopathy (DCM) itself is characterized by dilatation and impaired contraction of the left ventricle in the absence of underlying causes such as coronary artery disease (CAD), valve disease, and congenital heart disease. 9 Familial forms, defined by two or more affected relatives or by a first-degree relative who died unexplainably and suddenly before the age of 35, 10 were identified in up to 35% of cases. During the last 20 years, causative mutations have been described in >40 genes encoding proteins that play a role in the formation and function of the cytoskeleton as well as the sarcomere and nucleus including LMNA. 11 The majority of these genes only account for a minority of cases, and many mutations remain unique to one family. For that reason, it was an important step forward to group cardiomyopathies into specific morphological and functional phenotypes, and each phenotype is then subclassified into familial and nonfamilial forms. 9 Importantly, in this classification system, patients with identified de novo mutations, which mostly are monogenic, were assigned to the familial category as their disorder can be subsequently transmitted to their offspring. The ESC working group classification of cardiomyopathies greatly raised awareness of the genetic determinants of cardiomyopathies and strongly recommended the search for specific mutations, whenever appropriate. During the few last years, candidate gene approaches and genomewide genotyping, linkage analyses, and gene mapping for DCMassociated gene discovery have been widely used, 11 leading to more reliable data with regard to the frequency of different mutations, gender and age distribution, and, most importantly, genotype-phenotype correlations and prognosis in affected patients. With regard to LMNA mutations, different large cohorts from various countries (see van Spaendonck-Zwarts et al., 12 Parks et al., 13 and
Haas et al. 14 for the largest cohorts) were investigated and recent genotype-phenotype correlations were summarized in a metaanalysis on >2000 patients: 11 in a total of 10 studies, 2032 patients with familial and sporadic DCM were screened molecularly, resulting in a frequency of 5% for LMNA mutations. Around 69% of the patients were male and the mean age at diagnosis was 40 years. With regard to systolic function, 23 studies reported a left ventricular function of 35% in LMNA-positive DCM patients, which was lower when compared with patients with mutations in other genes. Heart
The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology. transplantation was performed in 27% of LMNA-positive DCM patients at a mean age of 41 years, and 61% patients showed supraventricular tachycardia (SVT) including atrial fibrillation, conduction disease (74%), and ventricular arrhythmias (50%), which is significantly higher when compared with other mutation carriers. In addition, in lamin A/C-positive DCM patients, the frequency of sudden cardiac death was higher compared with probands with preserved ventricular function (19% vs. 3%), and 26% of the implantable cardioverter defibrillator (ICD) carriers had adequate shocks; thus LMNA mutation causes severe and progressive DCM with poor outcome. On the other hand, it was reported, that LMNA mutation carriers without heart failure showed SVT in 13% of cases, 45% showed conduction system disorders, and 5% presented with ventricular arrhythmias. 11 The penetrance of developing DCM or left ventricular dysfunction reported was on average 45%, but data for this 'patient' population were derived from only six studies with a small number of probands. As LMNA mutation carriers have a poor prognosis, because of a high frequency of malignant arrhythmias and progression to endstage heart failure, identification of risk factors within this cohort was an important step forward. 15 In a multicentre cohort of 269 LMNA mutation carriers, non-sustained ventricular tachycardia, left ventricular ejection fraction <45% at the first clinical contact, and male sex were identified as independent risk factors for malignant ventricular arrhythmias. There was a cumulative risk per additional risk factor.
Young onset, high penetrance, and frequent need for heart transplantations 16 Today there are only few data on the onset of cardiac symptoms related to age in LMNA genotype-positive probands and family members, and also on the time of development of a cardiac phenotype in this population; with regard to this, the investigation by Hasselberg et al. added new and important information. Their approach to investigate patients and family members was facilitated as the Oslo University Hospital provides a national service for genetic testing of familial DCM for the whole of Norway. For that reason, all patients with suspected familial DCM were genetically tested in this institution and could be separated from those with idiopathic DCM. Further, genetic counselling and cascade genetic screening for family members without cardiac symptoms of LMNA genotype-positive probands was performed by the same group. For that reason, the authors were able to report on 561 unrelated DCM probands who were referred for genetic testing for familial DCM, of which 35 (6.2%) had a pathogenic LMNA mutation, comprising 18 different LMNA mutations. The LMNA prevalence was 6.2% among patients with familial DCM. Family genetic screening diagnosed a further 93 LMNA mutation-positive family members, and the authors were able to follow 79 (61%) of the total of 128 diagnosed LMNA genotype-positive subjects over more than 8 years. Age at first visit was 42 ± 16 years, and 36 (46%) of the subjects were female. Forty-eight (61%) of the subjects were probands and 31 (39%) were LMNA genotype-positive family members who were asymptomatic at genetic testing. The age at which a cardiac phenotype was penetrant did not differ between probands and family members, was 85% in the total LMNA population, and approached 100% at 60 years of age in both groups. Importantly, cardiac penetrance was higher than expected (61%) in asymptomatic LMNA genotypepositive family members and very early, at a mean age of 35 years. The annual incidence of newly documented cardiac phenotype was 9%, indicating rapid development of cardiac disease. Also the cardiac phenotype progressed during a relatively short follow-up period as indicated by the progression of atrioventricular conduction delay. The data show that onset of disease, disease severity, and disease progression in family members and in probands is severe and similar. Almost a quarter of LMNA patients died or needed a heart transplantation during 8 years of follow-up, and a quarter of patients with ICD received appropriate ICD therapy.
In summary, the study highlights the importance of early family screening in young family members and close cardiological follow-up of LMNA genotype-positive subjects as the majority of family members presented with conduction disease or arrhythmia without DCM. For that reason, clinicians should be aware of this condition, and genetic testing should also be offered to this patient group with the above-mentioned symptoms. There seems to be a strong predisposition to develop ventricular arrhythmias with fatal outcome, and the current study implies that there are characteristics other than left ventricular ejection fraction that may be used to identify LMNA patients at increased risk of sudden cardiac death, which may support the view that ICDs should be implanted earlier as current guidelines recommend. 17 Clinical algorithms to confirm a definite diagnosis in patients with cardiomyopathies and their family members including genotyping and phenotyping mostly follow the position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases related to genetic counselling, family screening, and genetic testing in families with a cardiomyopathy. 18 In addition, genetic screening for LMNA mutations should be strongly considered in young patients presenting with new atrioventricular block, conduction disease, ventricular arrhythmias, or atypical atrial arrhythmias, even in the absence of left ventricular dysfunction (Take home figure) . Clinical follow-up in LMNA genotype-positive index patients and, most importantly, in family members without cardiac phenotype should be close to minimize the risk of sudden cardiac death.
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